Creative Commons source reading · Clinical neurodiagnostics
Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5-90 years.
Joel Simrén; Ulf Andreasson; Johan Gobom; Marc Suarez Calvet; Barbara Borroni; Christopher Gillberg; Lars Nyberg; Roberta Ghidoni; Elisabeth Fernell; Mats Johnson; Herman Depypere; Caroline Hansson; Ingibjörg H Jonsdottir; Henrik Zetterberg; Kaj Blennow
Originally published in Brain communications · 2022-07-04
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
The recent development of assays that accurately quantify neurofilament light, a neuronal cytoskeleton protein, in plasma has generated a vast literature supporting that it is a sensitive, dynamic, and robust biomarker of neuroaxonal damage. As a result, efforts are now made to introduce plasma neurofilament light into clinical routine practice, making it an easily accessible complement to its cerebrospinal fluid counterpart. An increasing literature supports the use of plasma neurofilament light in differentiating neurodegenerative diseases from their non-neurodegenerative mimics and suggests it is a valuable biomarker for the evaluation of the effect of putative disease-modifying treatments (e.g. in multiple sclerosis). More contexts of use will likely emerge over the coming years. However, to assist clinical interpretation of laboratory test values, it is crucial to establish normal reference intervals. In this study, we sought to derive reliable cut-offs by pooling quantified plasma neurofilament light in neurologically healthy participants (5-90 years) from eight cohorts.
Discussion
In this study, we present a large material of normal plasma NfL concentrations from a large number of healthy participants spanning the ages 5–90 years. We derived specific cut-offs in five different age categories to reflect the clear effect of age on concentrations of plasma NfL. A clear effect of age was also reported in a study where Hviid et al.13 aimed to establish reference ranges for NfL.
Editorial reading guide
- Which patient population and reference standard did the authors use?
- Was the finding validated in a separate cohort, and how might patient selection affect it?
